Commission Implementing Decision (EU) 2025/439 of 28 February 2025 establishing a watch list of substances for Union-wide monitoring in the field of water policy pursuant to Directive 2008/105/EC of the European Parliament and of the Council (notified under document C(2025) 1244)

Article 1

The watch list of substances for Union-wide monitoring referred to in Article 8b of Directive 2008/105/EC is set out in the Annex to this Decision.

Article 2

Implementing Decision (EU) 2022/1307 is repealed.

Article 3

This Decision is addressed to the Member States.

Watch list of substances for Union-wide monitoring as set out in Article 8b of Directive 2008/105/EC

ANNEXSupplementary provisions

ANNEX Watch list of substances for Union-wide monitoring as set out in Article 8b of Directive 2008/105/EC Name of substance/group of substances Chemical Abstracts Service (CAS) number European Community (EC) number  ( 1 ) Indicative analytical method  ( 2 ) ,  ( 3 ) Maximum acceptable method quantification limit (ng/l) Fipronil 120068-37-3 424-610-5 SPE-HPLC-MS/MS 0,77 Clindamycin 18323-44-9 242-209-1 SPE-LC-MS/MS 44 Ofloxacin 82419-36-1 680-263-1 SPE-UHPLC-MS/MS 26 Metformin and Guanylurea  ( 4 ) 657-24-9 141-83-3 211-517-8 205-504-6 SPE-LC-MS/MS 156 000 100 000 Sunscreen agents  ( 5 ) Butyl methoxydibenzoyl-methane Octocrylene Benzophenone-3 Octisalate (2-ethylhexyl salicylate) 70356-09-1 6197-30-4 131-57-7 118-60-5 274-581-6 228-250-8 205-031-5 204-263-4 SPE-LC-ESI-MS/MS 3 000 266 670 168 N-1,3-Dimethylbutyl-N’-phenyl-p-phenylenediamine (6PPD) and 6PPD-quinone  ( 6 ) 793-24-8 2754428-18-5 212-344-0 893-269-6 SPE-LC-MS/MS 370 Abamectin  ( 7 ) Avermectin B1a and Avermectin B1b 71751-41-2 65195-55-3 65195-56-4 265-610-3 265-611-9 SPE-LC-MS/MS 1 Azole compounds  ( 8 ) Bromuconazole Climbazole Cyazofamid Difenoconazole Epoxiconazole Itraconazole Ketoconazole Mefentrifluconazole Propiconazole Triticonazole 116255-48-2 38083-17-9 120116-88-3 119446-68-3 133855-98-8 84625-61-6 65277-42-1 1417782-03-6 60207-90-1 131983-72-7 408-060-3 253-775-4 601-671-8 601-613-1 406-850-2 617-596-9 265-667-4 822-682-6 262-104-4 603-543-7 SPE-LC-MS/MS 15 110 130 360 180 8 50 1 600 1 000 1 000 Etoxazole 153233-91-1 604-891-2 SPE-GC-MS/MS 0,4 Fluoxetine 54910-89-3 611-209-7 SPE-LC-QTOF-HRMS 12 Propranolol 525-66-6 208-378-0 SPE-LC-MS/MS 20 Oxytetracycline and Tetracycline  ( 9 ) 79-57-2 60-54-8 201-212-8 200-481-9 SPE-LC-MS/MS 500 90 ( 1 )   Not available for all substances ( 2 )   All substances shall be monitored in whole water samples. ( 3 )   Extraction methods: SPE – solid-phase extraction Analytical methods: HPLC-MS/MS– High-performance liquid chromatography (tandem) triple quadrupole mass spectrometry LC-MS/MS – Liquid chromatography (tandem) triple quadrupole mass spectrometry LC-ESI-MS/MS – Liquid chromatography (tandem) triple quadrupole mass spectrometry with positive electrospray ionisation LC-QTOF-HRMS – Liquid chromatography quadrupole time-of-flight high-resolution mass spectrometry UHPLC-MS/MS – Ultra-high-performance liquid chromatography (tandem) triple quadrupole mass spectrometry ( 4 )   Metformin and guanylurea shall be analysed together in the same samples but reported as individual concentrations. ( 5 )   The sunscreen agents shall be analysed together in the same samples but reported as individual concentrations. ( 6 )   6PPD and 6PPD-quinone shall be analysed together in the same samples but reported as individual concentrations ( 7 )   The two major components of abamectin (B1a and B1b) shall be analysed together in the same samples and reported as a sum concentration. ( 8 )   The azole compounds shall be analysed together in the same samples but reported as individual concentrations. ( 9 )   Oxytetracycline and tetracycline shall be analysed together in the same samples but reported as individual concentrations.